New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:03 EDTBDSIBioDelivery Sciences completes enrollment for Phase 3 trial of Clonidine
BioDelivery Sciences has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the FDA. FDA has granted Fast Track designation for the program.
News For BDSI From The Last 14 Days
Check below for free stories on BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
September 8, 2014
08:52 EDTBDSIBioDelivery Sciences price target raised to $28 from $20 at Summer Street
Summer Street raised its price target for BioDelivery Sciences shares to $28 saying it left the company's analyst day on Friday incrementally more positive. The firm believes its sales estimates for Bunavail and BEMA Buprenorphine may prove to be conservative and reiterates a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use